News Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-05-23 pm EDT			5-day change	1st Jan Change
34.17 ^USD	+0.12%		-2.57%	-0.70%

May. 15	Mizuho Raises Price Target on Harmony Biosciences to $48 From $44, Keeps Outperform Rating	MT
May. 06	Harmony Biosciences Q1 Adjusted Earnings, Revenue Increase; 2025 Sales Outlook Reiterated	MT

Mizuho Raises Price Target on Harmony Biosciences to $48 From $44, Keeps Outperform Rating	May. 15	MT
Harmony Biosciences : HRMY Q1 2025 Earnings Presentation FINAL	May. 06	PU
Harmony Biosciences : HRMY Corporate Presentation May 6, 2025 FINAL	May. 06	PU
Harmony Biosciences Q1 Adjusted Earnings, Revenue Increase; 2025 Sales Outlook Reiterated	May. 06	MT
Harmony Biosciences Holdings, Inc., Q1 2025 Earnings Call, May 06, 2025	May. 06
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 06	CI
Earnings Flash (HRMY) Harmony Biosciences Posts Q1 Revenue $184.7M, vs. FactSet Est of $182.3M	May. 06	MT
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance	May. 06	BU
Earnings Flash (HRMY) Harmony Biosciences Holdings Reports Q1 Adjusted EPS $1.03	May. 06	MT
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Full Year 2025	May. 06	CI
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025	Apr. 29	BU
UBS Adjusts Price Target on Harmony Biosciences to $48 From $55, Maintains Buy Rating	Apr. 28	MT
BofA Cuts Price Target on Harmony Biosciences to $32 From $33	Apr. 21	MT
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome	Apr. 08	BU
Harmony Biosciences Holdings, Inc. Appoints Ron Philip to its Board of Directors, Audit Committee and Nominating and Corporate Governance Committee	Apr. 04	CI
Harmony Biosciences Appoints Biotech Leader Ron Philip To Its Board Of Directors	Apr. 03	RE
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors	Apr. 03	BU
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference	Mar. 26	BU
Harmony Biosciences Names Adam Zaeske As Chief Commercial Officer	Mar. 24	RE
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands	Mar. 24	BU
Harmony Biosciences Holdings, Inc. Announces Executive Changes	Mar. 24	CI
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm	Mar. 21	BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY	Mar. 17	PR
Mizuho Adjusts PT on Harmony Biosciences Holdings to $44 From $42, Maintains Outperform Rating	Mar. 17	MT
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY	Mar. 11	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Filters